David de Graaf, Ph.D.
President and Chief Executive Officer
Dr. David de Graaf joined Selventa in 2010 to define the company’s scientific strategy, direction and general operations. Additionally, he is responsible for developing key partnerships that will enhance the company’s significance.
Previously, Dr. de Graaf served as the Vice President of Biotherapeutics and Integrative Biology at Boehringer-Ingelheim, where he built a successful portfolio of clinical candidates, initiated key collaborations as well as managed scientific leadership and site operations. He also held roles with increasing responsibilities at Pfizer, AstraZeneca and the Whitehead/MIT Center for Genome Research with a focus on bringing innovative systems biology approaches to the early pipeline.
Dr. de Graaf completed his postdoctoral fellowship at the Weizmann Institute of Science in Rehovot, Israel in pharmacogenomics of human olfactory systems. He also earned a Ph.D. in mammalian genetics from The University of Illinois at Chicago and a Masters of Science degree in evolutionary genetics from the University of Utrecht in the Netherlands. He was awarded a Feinberg Fellowship and is invited frequently to speak at scientific conferences.
Chief Medical Officer
Dr. David A. Fryburg joined Selventa in 2011. His role is to critically oversee scientific strategies related to translational medicine and biomarker development. He brings over 20 years of clinical and pharmaceutical research experience to the team.
Previously, Dr. Fryburg was an Executive Director and Global Translational Medicine Lead for cardiovascular, metabolic and endocrine diseases at Pfizer. In these roles, he was responsible for the development, management and integration of diverse translational medicine strategies in these therapeutic areas across Pfizer’s R&D organization.
Dr. Fryburg served as an attending physician and a faculty member at the University of Virginia Health Sciences Center after completing his fellowship in endocrinology and metabolism at Yale University. Dr. Fryburg’s academic interests included the role of growth factors and hormones in metabolism and metabolic disorders, which were supported by numerous grant awards. He earned his M.D. from Albert Einstein College of Medicine of Yeshiva University and Bachelor of Arts from The Johns Hopkins University. He has more than 30 peer-reviewed research publications and is invited often to speak at scientific conferences.
Executive Vice President, Sales and Marketing
Mr. Louis Latino joined Selventa in 2008 to drive global sales supported by targeted marketing initiatives. He is building direct sales, sales support, marketing and business development infrastructure to support significant long-term growth consistent with the strategic direction of the company.
The majority of Mr. Latino’s career has focused on building value in a sales management capacity for early-stage life science companies. Prior to joining Selventa, Mr. Latino served as the Vice President of North America, Life Sciences Sales and Support for Accelrys, where he was responsible for both software and services. His more than 30 years of sales experience also included positions at Superscape Group PLC, Geneformatics and Biosym Technologies.
Mr. Latino earned a Bachelor of Science degree in chemistry from Boston College.
William Hayes, Ph.D.
Chief Technical Officer
Dr. William Hayes joined Selventa in 2012 to help implement advanced analytics as well as extend and refine Selventa Discovery Platform for biomarker discovery programs. He brings 15 years of experience managing and supporting innovative IT solutions. His responsibilities include extending the Selventa Discovery Platform to efficiently analyze new experimental assay data types and significantly increase the depth and breadth of capabilities for more sophisticated analyses.
Prior to joining Selventa, Dr. Hayes was the Director of Decision Support and Literature Informatics, R&D IT at Biogen Idec. In this role, he was responsible for providing decision support capabilities for R&D scientists. Notably, he evolved a Corporate Library into a Literature Informatics team using state of the art text analytics and visualizations to support Biogen Idec from Discovery to the Board Room and deployed an agile data management platform based on Semantic Web. Prior to Biogen Idec, William worked at AstraZeneca and GSK in the Bioinformatics Departments.
He received his Bachelor’s in Aerospace Engineering and Ph.D. in Applied Biology and Bioinformatics from Georgia Institute of Technology in Atlanta, GA.
Patricia F. Deware
Chief Financial Officer
Ms. Patricia Deware joined Selventa in 2011. She is responsible for providing the financial leadership for the company, including financial management and analysis, budgeting and forecasting, cash management, as well as tax and audit preparations.
She brings over 20 years of experience working in manufacturing, financial services, consulting and life science companies ranging from Fortune 500 to start-ups to the team. Notably, she was a controller for Diagnostic Vision Corporation. She also held senior or managing roles in South Bay Auto Group, Fidelity Investments, Di Pesa & Company, and Avery Dennison.
Ms. Deware received an M.B.A. from Babson College, Master of Taxation from Bentley College and a Bachelor of Science degree in Accounting from Stonehill College.
Renée Deehan Kenney, Ph.D.
Senior Vice President, Research and Development
Dr. Renée Deehan Kenney joined Selventa in 2006. As Head of Research, she develops and executes the scientific strategy for the organization. Together with her team of biologists and computational biologists, she is responsible for the scientific content behind ClarifyRA, a diagnostic that provides molecular information about Disease Activity and potential response to treatment for Rheumatoid Arthritis patients. Dr. Deehan Kenney also leads the science for Selventa's consulting services, and she leverages her understanding of both the industry and client needs to develop custom strategies that translate scientific challenges into navigable solutions. This is predicated on her fundamental belief that a comprehensive understanding of the molecular basis of disease, at the level of an individual patient, is required for successful target discovery and biomarker development and ultimately for personalized medicine in the clinic. Dr. Deehan Kenney has led over 45 collaborations with pharmaceutical, consumer product, and academic partners. She represents Selventa externally to clients, the Board of Directors and Selventa's Scientific Advisory Board, and she has spoken at personalized medicine conferences across the globe.
Dr. Deehan Kenney earned a Bachelor of Science in Engineering in bioengineering from the University of Pennsylvania and a Ph.D. in molecular and cell biology from the University of California, Berkeley.